These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 12381232)

  • 21. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 22. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 26. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
    Chong BH; Gallus AS; Cade JF; Magnani H; Manoharan A; Oldmeadow M; Arthur C; Rickard K; Gallo J; Lloyd J; Seshadri P; Chesterman CN;
    Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-induced thrombocytopaenia complicated by arterial and venous thrombosis: report of 2 cases successfully treated by a danaparoid sodium.
    Darling K; Jaumotte C; Saussoy P; Zech F; Lavenne E; Hainaut P
    Acta Clin Belg; 2000; 55(3):176-81. PubMed ID: 10981327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low molecular weight heparins and heparinoids.
    Eikelboom JW; Hankey GJ
    Med J Aust; 2002 Oct; 177(7):379-83. PubMed ID: 12358583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
    Salmi L; Leroy-Matheron C; LeBesnerais P; Rosanval O; Duvaldestin P; Gouault-Heilmann M
    Ann Fr Anesth Reanim; 2001 Nov; 20(9):799-802. PubMed ID: 11759322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venous thromboembolism in heparin-induced thrombocytopenia.
    Warkentin TE
    Curr Opin Pulm Med; 2000 Jul; 6(4):343-51. PubMed ID: 10912644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
    Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN
    Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ardeparin and danaparoid.
    Dimens Crit Care Nurs; 2000; 19(4):13-4. PubMed ID: 11998151
    [No Abstract]   [Full Text] [Related]  

  • 33. Current agents for the treatment of patients with heparin-induced thrombocytopenia.
    Warkentin TE
    Curr Opin Pulm Med; 2002 Sep; 8(5):405-12. PubMed ID: 12172444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
    Ben Ami R; Rachmimov R; Berliner S
    Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative review of the adverse effect profiles of heparins and heparinoids.
    Borris LC; Lassen MR
    Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.
    Yoshihara H; Sugiura-Ogasawara M; Kitaori T; Katano K; Ozaki Y
    Mod Rheumatol; 2020 Mar; 30(2):332-337. PubMed ID: 30924705
    [No Abstract]   [Full Text] [Related]  

  • 37. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group.
    Haemostasis; 1999; 29(6):310-7. PubMed ID: 10844404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Danaparoid sodium].
    Kitazawa Y
    Rinsho Byori; 2011 Feb; Suppl 147():164-6. PubMed ID: 21761765
    [No Abstract]   [Full Text] [Related]  

  • 39. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].
    Riedel R; Schmieder A; Koster A; Kim S; Baumgarten G; Schewe JC
    Med Klin Intensivmed Notfmed; 2017 May; 112(4):334-346. PubMed ID: 28005139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.